3//SEC Filing
OrbiMed Israel GP Ltd. 3
Accession 0000947871-21-000392
CIK 0001534248other
Filed
Mar 25, 8:00 PM ET
Accepted
Mar 26, 4:02 PM ET
Size
7.9 KB
Accession
0000947871-21-000392
Insider Transaction Report
Form 3
OrbiMed Israel GP Ltd.
10% Owner
Holdings
- 2,290,004(indirect: See Footnotes)
American Depository Shares
Holdings
- 2,290,004(indirect: See Footnotes)
American Depository Shares
Footnotes (3)
- [F1]Received in exchange for ordinary shares of Chemomab Ltd. in connection with the merger of Chemomab Ltd. into a wholly-owned subsidiary of the Issuer in accordance with the terms of an Agreement and Plan of Merger, dated as of December 14, 2020. Each American Depository Share ("ADS") represents twenty (20) ordinary shares of the Issuer.
- [F2]These securities of the Issuer are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the securities held directly by OIP noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP.
- [F3]This report is being jointly filed by OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
Chemomab Therapeutics Ltd.
CIK 0001534248
Entity typeother
IncorporatedIsrael
Related Parties
1- filerCIK 0001569590
Filing Metadata
- Form type
- 3
- Filed
- Mar 25, 8:00 PM ET
- Accepted
- Mar 26, 4:02 PM ET
- Size
- 7.9 KB